Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection

• Main Authors: Masaaki Mori (Author), Shinichi Watabe (Author), Tomoaki Taguchi (Author), Hisaya Hasegawa (Author), Mika Ishige (Author), Naoyuki Tanuma (Author), Akihiro Hirakawa (Author), Ryuji Koike (Author), Satoshi Kusuda (Author)
• Format: Book
• Published: BMC, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background The prophylactic use of anti-respiratory syncytial virus (RSV) antibody (palivizumab) for severe RSV infection is not approved in Japan in specified groups of infants with neuromuscular diseases or other rare diseases associated with reduced ventilation competence or difficulty i...